Related Articles
Sanofi takes on Novavax’s Covid vaccine for $500M, eyeing commercialization, flu combination
Sanofi is handing Novavax $500 million upfront to bring the biotech’s Covid-19 vaccine into the fold, with dual goals of co-commercializing the current vaccine and…
Takeda to shut down San Diego research center
Takeda is shuttering its San Diego research site, the company confirmed to Endpoints News. The company told employees on Thursday that it will close the…
Infectious disease biotech Bluejay raises $182M for hepatitis trials
California biotech Bluejay Therapeutics has secured a megaround to continue developing its treatment candidates for chronic hepatitis D and B. The $182 million Series C,…
After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials
A half-decade after a scientist’s reckless experiment with human embryos put a stop to much of China’s clinical work on CRISPR gene editing, local researchers…
AstraZeneca pulls Covid-19 vaccine globally as the pharma sees ‘no future commercial demand’
AstraZeneca is withdrawing its Oxford-collaborated Covid-19 vaccine from global markets, the UK-based pharma company confirmed in a statement to Endpoints News on Tuesday. The spokesperson…
As digital health unicorns are pressured to do more with less, Transcarent gets a fresh $126M
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Transcarent’s $126 million Series D round, which…
Exclusive: Feng Zhang CRISPR startup gathers patents, locking up rights to family of editing tech
In the bid to lock up patent rights to a growing suite of gene-editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT…
Flagship commits $50M to new startup that scours viral proteins for new drugs
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign:…
Exclusive: New York biotech debuts with $16M to find new ways to make solid cancer cell therapies
A new biotech is coming out of stealth with $16 million to develop cell therapies for solid cancers — an area where scientists have had…
Sen. Cassidy calls on Biden to do better at sharing H5N1 bird flu information
Senate HELP Committee ranking member Bill Cassidy (R-LA) is calling on the Biden administration to do a better job of communicating its findings on the…